engleski

Metastatic Soft Tissue Sarcoma Outcomes – Single Institutional Experience

Background: In this retrospective observational study, we analyzed characteristics and outcomes of patients with metastatic soft tissue sarcoma (mSTS), treated at our institution during the period of 2017 and 2018. Patients and Methods: 18 patients' records from databases of two institutes were analyzed. They were all patients with newly diagnosed mSTS and systemic treatment-naive. Results: 18 (54.5%) of all newly diagnosed STS patients (n=33) were initially metastatic, 11 males and 7 females. Liposarcoma accounted for 3 cases, while all other types for less (pleomorphic sarcoma, leiomyosarcoma, epithelioid sarcoma, angiosarcoma, and stromal gynecologic sarcoma: n=2, undifferentiated sarcoma, synovial sarcoma, rhabdomyosarcoma, extraosseal Ewing sarcoma, unclassified sarcoma: n=1). The most frequent metastatic site was lungs (72%). 11 patients (54.5%) received first-line systemic treatment, second and further lines 6, 4 and 2 patients, respectively. Median time-to- progression (TTP) interval with first-line treatment was 4 months, 4 months with second, and 3 months with third-line, Median overall survival (OS) for the 6 treated patients was 6 months and it is still not reached for 5 patients, with their medain treatment duration and follow-up of 14 months. Conclusion: Treatment choice depended on sarcoma type, patient age and co-morbidities, while supportive and palliative approach was reserved for those with poor performance status. This patient group is too small for any general conclusions on the outcomes, and it might be rational to compare these results with the ones from the larger patient group studies.

connective and soft tissue, neoplasms

nije evidentirano